New hope for rare leukemia: targeted pill shows promise in early trial

NCT ID NCT04409639

Ongoing Disease control Sponsor: University of Utah Source: ClinicalTrials.gov ↗

First seen Nov 21, 2025 · Last updated May 17, 2026 · Updated 15 times

Summary

This study tests a drug called cobimetinib in people with a rare blood cancer (CMML) that has certain gene mutations. The goal is to see if the drug can shrink or control the cancer. The trial includes 14 adults who are either newly diagnosed or whose cancer stopped responding to a previous treatment. Participants take the drug daily for 3 weeks, then a week off, and are monitored for response and side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Fred Hutchinson Cancer Research Center

Seattle, Washington, 98109, United States
Huntsman Cancer Institute at University of Utah

Salt Lake City, Utah, 84112, United States
Oregon Health and Science University

Portland, Oregon, 97239, United States

Conditions

Explore the condition pages connected to this study.

CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)